Miguel Malespin1, Ciel Harris2, Ozdemir Kanar2, Kelly Jackman2, Carmen Smotherman3, Abbey Johnston4, Julie Ferm4, Silvio W de Melo2, James S Scolapio2, David R Nelson5, Scott J Cotler6. 1. Department of Medicine, University of Florida Health, Jacksonville, FL, United States. Electronic address: miguel.malespin@jax.ufl.edu. 2. Department of Medicine, University of Florida Health, Jacksonville, FL, United States. 3. Center for Health Equity and Quality Research (CHEQR), University of Florida, Jacksonville, FL, United States. 4. Department of Pharmacy, University of Florida Health, Jacksonville, FL, United States. 5. Clinical and Translational Science Institute, University of Florida, Gainesville, FL, United States. 6. Division of Hepatology, Loyola University Medical Center, Maywood, IL, United States.
Abstract
INTRODUCTION AND AIM: Direct-acting antiviral (DAA) agents are highly effective for treatment of chronic hepatitis C virus (HCV) yet access to treatment remains a serious challenge. The aim of this study was to identify barriers to treatment initiation with DAA-containing regimens in an urban clinic setting. MATERIALS AND METHODS: A retrospective cohort of all chronic HCV patients seen in an urban academic practice in Jacksonville, FL, USA from 1/2014 to 1/2017 was analyzed. Baseline characteristics were recorded and a review of medical records was performed to identify barriers to treatment initiation and overall success rates. RESULTS: Two-hundred and forty patients with chronic HCV were analyzed. Fifty-six percent of patients were African-American and 63% were insured through Medicaid/county programs or uninsured. Sixty-nine percent had barriers to initiating antiviral therapy categorized as psychosocial (n=112), provider (n=26), medical (n=20), and insurance-related factors (n=7). The most commonly encountered psychosocial barriers included failure to keep appointments (79/240, 33%), active substance abuse (18/240, 8%), and failure to obtain laboratory testing (11/240, 5%). Overall, only 27% of patients evaluated were initiated on DAA-containing regimens with 18% reaching SVR12 within the 36-month study period. CONCLUSION: In conclusion, only 27% of patients who presented to an urban academic practice with chronic HCV received DAA-containing regimens over a 36-month period. Psychosocial issues were the major barriers to antiviral therapy. These findings illustrate the need for an integrated approach that addresses psychosocial factors as well as comorbidities and adherence to care in order to increase rates of HCV treatment in at risk patients.
INTRODUCTION AND AIM: Direct-acting antiviral (DAA) agents are highly effective for treatment of chronic hepatitis C virus (HCV) yet access to treatment remains a serious challenge. The aim of this study was to identify barriers to treatment initiation with DAA-containing regimens in an urban clinic setting. MATERIALS AND METHODS: A retrospective cohort of all chronic HCVpatients seen in an urban academic practice in Jacksonville, FL, USA from 1/2014 to 1/2017 was analyzed. Baseline characteristics were recorded and a review of medical records was performed to identify barriers to treatment initiation and overall success rates. RESULTS: Two-hundred and forty patients with chronic HCV were analyzed. Fifty-six percent of patients were African-American and 63% were insured through Medicaid/county programs or uninsured. Sixty-nine percent had barriers to initiating antiviral therapy categorized as psychosocial (n=112), provider (n=26), medical (n=20), and insurance-related factors (n=7). The most commonly encountered psychosocial barriers included failure to keep appointments (79/240, 33%), active substance abuse (18/240, 8%), and failure to obtain laboratory testing (11/240, 5%). Overall, only 27% of patients evaluated were initiated on DAA-containing regimens with 18% reaching SVR12 within the 36-month study period. CONCLUSION: In conclusion, only 27% of patients who presented to an urban academic practice with chronic HCV received DAA-containing regimens over a 36-month period. Psychosocial issues were the major barriers to antiviral therapy. These findings illustrate the need for an integrated approach that addresses psychosocial factors as well as comorbidities and adherence to care in order to increase rates of HCV treatment in at risk patients.
Authors: Xinyi Jiang; Hyun Jin Song; Wei Wang; Linda Henry; Lindsey M Childs-Kean; Vincent Lo Re; Haesuk Park Journal: J Manag Care Spec Pharm Date: 2021-07
Authors: Oluwaseun Falade-Nwulia; Rachel E Gicquelais; Jacquie Astemborski; Sean D McCormick; Greg Kirk; Mark Sulkowski; David L Thomas; Shruti H Mehta Journal: Liver Int Date: 2020-10 Impact factor: 8.754
Authors: Christer Frode Aas; Jørn Henrik Vold; Svetlana Skurtveit; Ingvild Odsbu; Fatemeh Chalabianloo; Jan Magnus Økland; Rafael Alexander Modahl Leiva; Peter Vickerman; Kjell Arne Johansson; Lars T Fadnes Journal: BMJ Open Date: 2020-08-26 Impact factor: 2.692